A769662, a novel activator of AMP‐activated protein kinase, inhibits non‐proteolytic components of the 26S proteasome by an AMPK‐independent mechanism
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In this work we present evidence that A769662, a novel activator of AMP‐activated protein kinase (AMPK), is able to inhibit the function of the 26S proteasome by an AMPK‐independent mechanism. Contrary to the mechanism of action of most proteasome inhibitors, A769662 does not affect the proteolytic activities of the 20S core subunit, defining in this way a novel mechanism of inhibition of 26S proteasome activity. Inhibition of proteasome activity by A769662 is reversible and leads to an arrest of cell cycle progression. These side effects of this new activator of AMPK should be taken into account when this compound is used as an alternative activator of the kinase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proteolysis: from the lysosome to ubiquitin and the proteasome
Ciechanover, A. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1552 · Cited by 1,133 · cited 1×
“protein degradation in mammalian cells [1–4].”
Sanders, M. J., Ali, Z. S., Hegarty, B. D., Heath, R., Snowden, M. A., & Carling, D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706543200 · Cited by 347 · cited 1×
“are not related to AMPK activation, we decided to confirm our results by the use of the A769662 compound, a novel activator of AMPK ([11], [12], [13]).”
Method
Cited by
AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome
Zhang, B. B., Zhou, G., & Li, C. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.03.012 · Cited by 1,026
AMPK activators: mechanisms of action and physiological activities
Kim, J., Yang, G., Kim, Y., Kim, J., & Ha, J. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.16 · Cited by 817
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth
Shaw, R. J. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01972.x · Cited by 644
“The fact that the targeted Abbott compound also performed well suggests that AMPK is in fact the key target of the biguanides in tumour reduction, though off-target effects of the Abbott compound have also been reported (Moreno et al. 2008).”
BackgroundCellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway
Mo, J.-S., Meng, Z., Kim, Y. C., Park, H. W., Hansen, C. G., Kim, S., Lim, D.-S., & Guan, K.-L. (2015) · Nature Cell Biology · doi:10.1038/ncb3111 · Cited by 557
PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis
Schultze, S. M., Hemmings, B. A., Niessen, M., & Tschopp, O. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002109 · Cited by 540
AMPK activation: a therapeutic target for type 2 diabetes?
Saha, A., Coughlan, K., Valentine, R., & Ruderman, N. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s43731 · Cited by 429
Pharmacological approaches to restore mitochondrial function
Andreux, P. A., Houtkooper, R. H., & Auwerx, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4023 · Cited by 383
Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer
Fogarty, S., & Hardie, D. G. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.09.012 · Cited by 350
Mitochondria as a Therapeutic Target in Heart Failure
Bayeva, M., Gheorghiade, M., & Ardehali, H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1021 · Cited by 332
Unraveling the regulation of hepatic gluconeogenesis
Zhang, X., Yang, S., Chen, J., & Su, Z. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00802 · Cited by 314
“In addition to being an AMPK activator, A-769662 is found to inhibit Na+-K+ATPase in L6 skeletal muscle cells or non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism (79, 80).”
BackgroundActivation and Signaling by the AMP-Activated Protein Kinase in Endothelial Cells
Fisslthaler, B., & Fleming, I. (2009) · Circulation Research · doi:10.1161/circresaha.109.201590 · Cited by 295
The fat side of prostate cancer
Zadra, G., Photopoulos, C., & Loda, M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.03.010 · Cited by 291
AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation
Gélinas, R., Mailleux, F., Dontaine, J., Bultot, L., Demeulder, B., Ginion, A., Daskalopoulos, E. P., Esfahani, H., Dubois-Deruy, E., Lauzier, B., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02795-4 · Cited by 253
Self-citationScott, J. W., van Denderen, B. J. W., Jorgensen, S. B., Honeyman, J. E., Steinberg, G. R., Oakhill, J. S., Iseli, T. J., Koay, A., Gooley, P. R., Stapleton, D., et al. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.10.005 · Cited by 252
CDK4 Phosphorylates AMPKα2 to Inhibit Its Activity and Repress Fatty Acid Oxidation
Lopez-Mejia, I. C., Lagarrigue, S., Giralt, A., Martinez-Carreres, L., Zanou, N., Denechaud, P.-D., Castillo-Armengol, J., Chavey, C., Orpinell, M., Delacuisine, B., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.034 · Cited by 71
Self-citationEstradiol effects on hypothalamic AMPK and BAT thermogenesis: A gateway for obesity treatment?
López, M., & Tena-Sempere, M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.014 · Cited by 70
The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma
Lospinoso Severini, L., Ghirga, F., Bufalieri, F., Quaglio, D., Infante, P., & Di Marcotullio, L. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1823967 · Cited by 61
PKC-Dependent Human Monocyte Adhesion Requires AMPK and Syk Activation
Chang, M.-Y., Huang, D.-Y., Ho, F.-M., Huang, K.-C., & Lin, W.-W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040999 · Cited by 54
“5 mM) or A769662 (10 mM) alone, two AMPK activators [20], did not affect monocyte”
Background
Metadata
- Authors
- Moreno, D., Knecht, E., Viollet, B., & Sanz, P.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2008-06-30
- Volume
- 582
- Issue
- 17
- Pages
- 2650-2654
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W2095358591
- Cited by
- 94
- References
- 2
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.